JAK Inhibitors Taking on Psoriatic Arthritis

Abstract

Psoriasis is a chronic inflammatory skin disease that affects 2 to 4% of the population.¹ Inflammatory arthritis develops in approximately 30% of patients with psoriasis and can have a major effect on activities of daily living and quality of life.² Peripheral joint involvement in patients with psoriatic arthritis can be oligoarticular or polyarticular and can cause joint destruction. Several medications are used to treat psoriatic arthritis, and the choice of agent and the timing of administration in the course of the disease depend on disease manifestations, their severity, and prognostic factors.² Therapy typically involves the sequential use of nonsteroidal antiinflammatory . . .